1 A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. 2  Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear.
Bravecto (fluralaner) is a systemic antiparasitic drug introduced to the veterinary market by Merck in 2014. A 7 March 2014 study published in the journal Parasites & Vectors (based upon a study of 32 beagles treated with fluralaner) observed no serious adverse side effects attributed to the medication:
The update also asserted that BRAVECTO chewables were responsible for the dogâs death and that several other dogs had died of liver and kidney failure shortly after taking the same medication. (No information was provided showing or explaining a causal link between the dead dog and BRAVECTO chewables other than a post hoc ergo propter hoc assumption.) Bravecto (fluralaner) is a systemic antiparasitic drug introduced to the veterinary market by Merck in 2014.